Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 174

Similar articles for PubMed (Select 23344560)

1.

Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.

Viruses. 2013 Jan 11;5(1):127-49. doi: 10.3390/v5010127. Review.

2.

Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Yu X, Lu L, Cai L, Tong P, Tan S, Zou P, Meng F, Chen YH, Jiang S.

J Virol. 2012 Jan;86(1):589-93. doi: 10.1128/JVI.05066-11. Epub 2011 Oct 19.

3.
4.

A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.

Pan C, Cai L, Lu H, Lu L, Jiang S.

J Biol Chem. 2011 Aug 12;286(32):28425-34. doi: 10.1074/jbc.M111.241992. Epub 2011 Jun 20.

5.

Peptide and non-peptide HIV fusion inhibitors.

Jiang S, Zhao Q, Debnath AK.

Curr Pharm Des. 2002;8(8):563-80. Review.

PMID:
11945159
7.

HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.

Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.

Biochim Biophys Acta. 2012 Dec;1818(12):2950-7. doi: 10.1016/j.bbamem.2012.07.020. Epub 2012 Jul 31.

8.

ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.

Yu F, Lu L, Liu Q, Yu X, Wang L, He E, Zou P, Du L, Sanders RW, Liu S, Jiang S.

Biochim Biophys Acta. 2014 May;1838(5):1296-305. doi: 10.1016/j.bbamem.2013.12.022. Epub 2014 Jan 3.

9.

Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.

He Y, Cheng J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q.

J Virol. 2008 Jul;82(13):6349-58. doi: 10.1128/JVI.00319-08. Epub 2008 Apr 16.

10.

Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.

He Y.

Curr Pharm Des. 2013;19(10):1800-9. Review.

PMID:
23092277
11.

Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Champagne K, Shishido A, Root MJ.

J Biol Chem. 2009 Feb 6;284(6):3619-27. doi: 10.1074/jbc.M809269200. Epub 2008 Dec 10.

12.

HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.

Liu S, Wu S, Jiang S.

Curr Pharm Des. 2007;13(2):143-62. Review.

PMID:
17269924
13.
15.

Development of HIV-1 fusion inhibitors targeting gp41.

Lu K, Asyifah MR, Shao F, Zhang D.

Curr Med Chem. 2014 Jun;21(17):1976-96. Review.

PMID:
24350848
16.

Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.

Bai Y, Xue H, Wang K, Cai L, Qiu J, Bi S, Lai L, Cheng M, Liu S, Liu K.

Amino Acids. 2013 Feb;44(2):701-13. doi: 10.1007/s00726-012-1394-8. Epub 2012 Sep 9.

PMID:
22961335
17.

Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.

Chao L, Lu L, Yang H, Zhu Y, Li Y, Wang Q, Yu X, Jiang S, Chen YH.

PLoS One. 2013 May 31;8(5):e66156. doi: 10.1371/journal.pone.0066156. Print 2013.

18.

Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.

Cai L, Jiang S.

ChemMedChem. 2010 Nov 8;5(11):1813-24. doi: 10.1002/cmdc.201000289. Review.

PMID:
20845360
19.

HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.

Pan C, Liu S, Jiang S.

J Formos Med Assoc. 2010 Feb;109(2):94-105. doi: 10.1016/S0929-6646(10)60029-0. Review.

PMID:
20206833
20.

Is there a future for antiviral fusion inhibitors?

Berkhout B, Eggink D, Sanders RW.

Curr Opin Virol. 2012 Feb;2(1):50-9. doi: 10.1016/j.coviro.2012.01.002. Epub 2012 Jan 28. Review.

PMID:
22440966
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk